MY126132A - Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases - Google Patents

Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases

Info

Publication number
MY126132A
MY126132A MYPI20013985A MYPI20013985A MY126132A MY 126132 A MY126132 A MY 126132A MY PI20013985 A MYPI20013985 A MY PI20013985A MY PI20013985 A MYPI20013985 A MY PI20013985A MY 126132 A MY126132 A MY 126132A
Authority
MY
Malaysia
Prior art keywords
signal transduction
tyrosine kinases
aminoquinazolines
inhibit signal
transduction mediated
Prior art date
Application number
MYPI20013985A
Other languages
English (en)
Inventor
Frank Dr Himmelsbach
Elke Dr Langkopf
Birgit Dr Jung
Stefan Dr Blech
Flavia Dr Solca
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY126132A publication Critical patent/MY126132A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20013985A 2000-08-26 2001-08-24 Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases MY126132A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10042058A DE10042058A1 (de) 2000-08-26 2000-08-26 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
MY126132A true MY126132A (en) 2006-09-29

Family

ID=7653945

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20013985A MY126132A (en) 2000-08-26 2001-08-24 Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases

Country Status (30)

Country Link
EP (1) EP1315705A1 (cs)
JP (1) JP4834282B2 (cs)
KR (1) KR100862873B1 (cs)
CN (1) CN100404517C (cs)
AR (1) AR033562A1 (cs)
AU (2) AU2001287694B2 (cs)
BG (1) BG107559A (cs)
BR (1) BR0113519A (cs)
CA (1) CA2417897C (cs)
CZ (1) CZ302567B6 (cs)
DE (1) DE10042058A1 (cs)
EA (1) EA005679B1 (cs)
EC (1) ECSP034464A (cs)
EE (1) EE05269B1 (cs)
HR (1) HRP20030138A2 (cs)
HU (1) HUP0300819A3 (cs)
IL (2) IL154602A0 (cs)
ME (1) MEP58708A (cs)
MX (1) MXPA03001483A (cs)
MY (1) MY126132A (cs)
NO (1) NO324866B1 (cs)
NZ (1) NZ524668A (cs)
PL (1) PL360248A1 (cs)
RS (1) RS52279B (cs)
SK (1) SK287747B6 (cs)
TW (1) TWI294422B (cs)
UA (1) UA73004C2 (cs)
UY (1) UY26903A1 (cs)
WO (1) WO2002018351A1 (cs)
ZA (1) ZA200300991B (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP45508A (en) 1999-06-21 2011-02-10 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
JP4776882B2 (ja) * 2002-03-30 2011-09-21 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10214412A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
DE10326186A1 (de) * 2003-06-06 2004-12-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
DE602004013806D1 (en) 2003-09-16 2008-06-26 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
DE10345875A1 (de) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10350717A1 (de) * 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ATE521603T1 (de) 2005-02-26 2011-09-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
KR100673775B1 (ko) * 2005-04-08 2007-01-24 엘지전자 주식회사 냉장고용 홈바
CA2619037A1 (en) * 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
WO2007054550A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
CA2643363A1 (en) * 2006-03-09 2007-09-13 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them
PL2068880T3 (pl) 2006-09-18 2012-09-28 Boehringer Ingelheim Int Sposób leczenia raka z mutacjami EGFR
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
SI2245026T1 (sl) 2008-02-07 2012-12-31 Boehringer Ingelheim International Gmbh Spirociklični heterocikli, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
KR102187034B1 (ko) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
ME03041B (me) 2013-03-06 2018-10-20 Astrazeneca Ab Inhibitori hinazolina aktivirajućih mutantnih oblika receptora epidermalnog faktora rasta
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
MA39837B1 (fr) * 2014-04-04 2020-05-29 H Lundbeck As Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
US20170176028A1 (en) 2015-12-18 2017-06-22 Lg Electronics Inc. Air conditioner
CA3044432A1 (en) 2016-11-17 2018-05-24 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations
CN112321814B (zh) * 2020-12-30 2021-03-23 广州初曲科技有限公司 一种吉非替尼艾地苯醌轭合物的制备及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SI0880508T1 (en) * 1996-02-13 2003-10-31 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
KR100489174B1 (ko) * 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
RO121900B1 (ro) * 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
KR20030024914A (ko) 2003-03-26
IL154602A (en) 2008-07-08
EA200300219A1 (ru) 2003-08-28
WO2002018351A1 (de) 2002-03-07
UY26903A1 (es) 2002-03-22
MEP58708A (en) 2011-05-10
HK1057557A1 (zh) 2004-04-08
EE200300077A (et) 2004-12-15
MXPA03001483A (es) 2003-06-06
NZ524668A (en) 2006-06-30
CA2417897A1 (en) 2003-01-30
PL360248A1 (en) 2004-09-06
EA005679B1 (ru) 2005-04-28
AR033562A1 (es) 2003-12-26
CZ302567B6 (cs) 2011-07-13
AU2001287694B2 (en) 2007-09-06
IL154602A0 (en) 2003-09-17
BG107559A (bg) 2003-10-31
JP2004507529A (ja) 2004-03-11
UA73004C2 (uk) 2005-05-16
CA2417897C (en) 2009-03-31
NO20030870D0 (no) 2003-02-25
SK287747B6 (sk) 2011-08-04
SK2312003A3 (en) 2003-10-07
ZA200300991B (en) 2004-04-16
YU14003A (sh) 2006-01-16
HRP20030138A2 (en) 2005-04-30
EP1315705A1 (de) 2003-06-04
NO20030870L (no) 2003-02-25
HUP0300819A2 (hu) 2003-09-29
BR0113519A (pt) 2003-07-01
DE10042058A1 (de) 2002-03-07
EE05269B1 (et) 2010-02-15
KR100862873B1 (ko) 2008-10-15
TWI294422B (en) 2008-03-11
RS52279B (en) 2012-10-31
CN1449390A (zh) 2003-10-15
AU8769401A (en) 2002-03-13
JP4834282B2 (ja) 2011-12-14
NO324866B1 (no) 2007-12-17
CN100404517C (zh) 2008-07-23
ECSP034464A (es) 2003-03-31
HUP0300819A3 (en) 2008-03-28

Similar Documents

Publication Publication Date Title
MY126132A (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
MY136086A (en) Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
MY127771A (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
IL173916A0 (en) Thienopyrazoles
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
NZ515392A (en) Respiratory syncytial virus replication inhibitors
PL351125A1 (en) Derivatives of 4,5-diaryl-3(2)-furanone as inhibitors of cykoxygenease-2
GEP20063868B (en) Combination therapy for the treatment of cancer
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
MXPA05008780A (es) Heterociclos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y preocedimientos para su preparacion.
TW200510341A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
WO2003072537A3 (en) Selective protein tyrosine phosphatatase inhibitors
PT1255538E (pt) Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros
TW200504051A (en) Novel acridine derivatives and their use as medicaments
EA200500865A1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
IL162820A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors